This technology uses fenretinide, a synthetic vitamin A derivative, to boost the body’s adaptive immune response after vaccination or infection, making vaccines more effective, especially for poorly immunogenic agents or immunocompromised individuals, without increasing infection severity.
The field of vaccine development and immunotherapy is critical for controlling infectious diseases and protecting vulnerable populations. Effective vaccines rely on the body’s ability to mount a strong and lasting adaptive immune response, which is often facilitated by adjuvants—substances added to vaccines to enhance immunogenicity. However, many vaccines, particularly those targeting emerging pathogens or used in immunocompromised individuals, elicit suboptimal immune responses. This challenge is compounded in settings where dose sparing is necessary, such as during pandemics or when manufacturing capacity is limited. There is a growing need for novel strategies that can reliably boost immune responses, especially for populations with weakened immunity due to age, underlying disease, or immunosuppressive treatments. Current approaches to enhancing vaccine efficacy and immune responses face several limitations. Traditional adjuvants, such as aluminum salts or oil-in-water emulsions, can be associated with increased reactogenicity, complex manufacturing requirements, and regulatory hurdles, which slow down the development and deployment of new vaccines. Moreover, these adjuvants are not always effective for all vaccine types or in all patient populations, leaving gaps in protection for those most at risk. In immunocompromised individuals, even potent adjuvants may fail to elicit adequate immunity, and there are few safe, broadly applicable alternatives. As a result, there is a pressing need for new immune-enhancing approaches that are safe, effective across diverse populations, and compatible with existing vaccine platforms.
This technology utilizes fenretinide (N-(4-hydroxyphenyl)retinamide), a synthetic derivative of vitamin A, as a universal immune adjuvant to enhance adaptive immune responses following vaccination or pathogen exposure. When administered after inoculation, fenretinide specifically increases serum levels of key cytokines—IP-10 and IFN-gamma—both of which are critical for T cell activation and effector function. Importantly, this immunomodulatory effect occurs without altering the course of infection or affecting viral titers, as demonstrated in clinical trials involving dengue virus. The approach is particularly valuable in scenarios where vaccines are poorly immunogenic, where individuals are immunocompromised, or where dose sparing is necessary for safety or production efficiency. Fenretinide’s favorable toxicity profile, established through its prior use in cancer prevention, further supports its suitability for broad application as an immune response enhancer. What differentiates this technology is its unique mechanism of action and versatility. Unlike traditional adjuvants, which often require complex development and can introduce regulatory and manufacturing challenges, fenretinide acts post-inoculation to selectively boost adaptive immunity without increasing inflammation or viral replication. This allows for improved immune responses even in vulnerable populations, such as the elderly or immunosuppressed, and enables more efficient use of vaccine doses. Additionally, its ability to function as an adjuvant substitute offers significant advantages in terms of reducing research and development costs and streamlining regulatory approval. The method’s demonstrated efficacy in human challenge models, combined with its broad applicability and established safety, positions it as a transformative solution for enhancing vaccine performance and infectious disease management.
Photo for reference only, not a depiction of the invention.
• Enhances adaptive immune responses by increasing key cytokines (IP-10 and IFN-gamma) associated with T cell activation and effector function
• Acts as a universal immune adjuvant effective when administered post-inoculation with pathogens or vaccines
• Improves immune responses to poorly immunogenic vaccines and immunostimulatory agents
• Boosts immunity in immunocompromised individuals, including those undergoing chemotherapy or radiation
• Enables dose sparing, reducing the amount of vaccine or immunostimulant needed
• Provides an alternative to traditional adjuvants, potentially lowering R&D, manufacturing, and regulatory costs
• Does not alter the course of infection or viral titers, focusing on immune enhancement rather than direct antiviral effects
• Universal vaccine immune adjuvant
• Enhancing immunity in immunocompromised
• Dose sparing for vaccines
• Adjuvant substitute for vaccine development
Patent application 63/861,507 filed 8/11/2025
TRL 7
The technology is at an early clinical development stage, supported by human challenge study data demonstrating enhanced adaptive immune responses (increased IP 10 and IFN γ) without altering infection course or viral titers. Further clinical evaluation in targeted vaccine and infectious disease indications would advance it toward TRL 8.
This technology is available for licensing.